Episode Details

Toronto researchers are pioneering liquid biopsies—blood tests that detect microscopic tumor DNA after cancer treatment—to catch recurrence early and spare patients unnecessary harsh therapies. With newfound sensitivity, these tests are revealing hidden cancer signals, like Paul Lonergan’s case, where early detection led to life-saving intervention. A massive five-year study involving 7,000+ patients is now underway to validate the technology’s reliability, potentially linking positive results to new treatments and negative ones to treatment avoidance. While still evolving, this breakthrough could redefine cancer care—offering hope for a future where precision and prevention guide every step.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/152412f0ee0f1403